Publication, Part of Case-mix Adjusted Percentage of Cancers Diagnosed at Stages 1 and 2 in England
Case-mix adjusted percentage of cancers diagnosed at stages 1 and 2 in England, 2019
Official statistics
Unadjusted percentage of cancers diagnosed at stages 1 and 2 by cancer site/group and deprivation, 2019
Cancer site/group
Table 1 lists the unadjusted percentage of cancers diagnoses at stages 1 and 2 by cancer site/group in 2019. Of the cancer sites/groups listed, the percentage of cases diagnosed at stages 1 and 2 ranged from 19.7% (oesophagus including cardia and gastroesophageal junction) to 90.2% (testis). The percentage of cancers diagnosed at stages 1 and 2 may vary by cancer site/group for several reasons. These reasons include: patient awareness and recognition of symptoms, the ease of diagnosis of the symptoms by healthcare practitioners (cancers with non-specific symptoms can be harder to diagnose), and how fast the cancer spreads and develops.
Table 1. Unadjusted percentage of cancers diagnosed at stages 1 and 2 by cancer site/group (2019)
|
Cancer site/group |
Number of cancers diagnosed at stages 1 and 2 |
Total number of stageable cancers diagnosed |
Percentage diagnosed at stages 1 and 2 (%) |
|
Testis |
1,304 |
1,445 |
90.2 |
|
Melanoma of skin |
11,587 |
13,008 |
89.1 |
|
Thyroid* |
1,831 |
2,069 |
88.5 |
|
Breast |
33,807 |
39,467 |
85.7 |
|
Uterus |
5,593 |
6,921 |
80.8 |
|
Bladder |
4,647 |
6,152 |
75.5 |
|
Cervix* |
954 |
1,337 |
71.4 |
|
Kidney, except renal pelvis |
3,993 |
7,098 |
56.3 |
|
Larynx including anterior surface of epiglottis |
786 |
1,442 |
54.5 |
|
Oropharynx, base of tongue, tonsil, soft palate and uvula |
1,732 |
3,247 |
53.3 |
|
Prostate |
19,968 |
37,483 |
53.3 |
|
Colon |
9,409 |
20,494 |
45.9 |
|
Hodgkin lymphoma |
642 |
1,400 |
45.9 |
|
Oral cavity, hard palate and lip (inner aspect) |
1,055 |
2,397 |
44.0 |
|
Rectum and rectosigmoid junction |
4,434 |
10,263 |
43.2 |
|
Ovary, fallopian tube and primary peritoneal carcinomas |
2,008 |
5,090 |
39.4 |
|
Stomach excluding cardia and gastroesophageal junction* |
809 |
2,437 |
33.2 |
|
Lung |
10,640 |
34,974 |
30.4 |
|
Non-Hodgkin lymphoma |
2,138 |
8,310 |
25.7 |
|
Pancreas |
1,463 |
6,450 |
22.7 |
|
Oesophagus including cardia and gastroesophageal junction |
1,363 |
6,905 |
19.7 |
* Staging completeness for 2019 was below 65% for cervix, stomach, and thyroid cancers.
Deprivation
All stageable cancers are included within this section, this includes the 21 cancer sites/groups in Table 1 plus other stageable cancer sites defined according to the United Kingdom and Ireland Association of Cancer Registries (UKIACR).
Table 2 shows that the unadjusted percentage of cancers diagnosed at stages 1 and 2 varies by deprivation quintile for England. In 2019, the percentage of cancers diagnosed at stages 1 and 2 in the 20% most deprived areas of England is 7.8 percentage points lower than for those in the 20% least deprived areas (49.8% versus 57.6%), this is significantly lower.
Table 2. Unadjusted percentage of cancers diagnosed at stages 1 and 2 by deprivation (2019)
|
Deprivation Quintile |
Number of cancers diagnosed at stages 1 and 2 |
Total number of stageable cancers diagnosed* |
Percentage diagnosed at stages 1 and 2 (%) |
|
5 – least deprived |
29,184 |
50,432 |
57.9 |
|
4 |
28,317 |
50,747 |
55.8 |
|
3 |
26,629 |
48,595 |
54.8 |
|
2 |
23,035 |
43,684 |
52.7 |
|
1 – most deprived |
20,798 |
41,509 |
50.1 |
* stageable cancers includes 21 cancer sites in Table 1 plus other stageable cancers defined according to the United Kingdom and Ireland Association of Cancer Registries
Cancer site/group and deprivation
Table 3 shows that of the 21 cancer sites/groups investigated, 10 had a significantly lower percentage of cancers diagnosed at stages 1 and 2 in the 20% most deprived areas compared to those in the 20% least deprived areas, 10 cancer sites/groups had no significant difference and 1 cancer site/group (ovary) had a significantly higher percentage of cancers diagnosed at stages 1 and 2 (44.8% compared to 37.0%).
Table 3. Unadjusted percentage of cancers diagnosed at stages 1 and 2 by cancer site/group and deprivation (2019)
|
Cancer site/group |
Percentage of cancers diagnosed at stages 1 and 2 in most deprived quintile |
Percentage of cancers diagnosed at stages 1 and 2 in least deprived quintile |
Statistically significant difference? |
|
Bladder |
74.1 |
78.2 |
Yes |
|
Breast |
84.0 |
87.2 |
Yes |
|
Cervix* |
64.5 |
73.5 |
Yes |
|
Colon |
45.1 |
46.6 |
No |
|
Hodgkin lymphoma |
45.2 |
47.3 |
No |
|
Kidney, except renal pelvis |
56.5 |
57.5 |
No |
|
Larynx including anterior surface of epiglottis |
48.2 |
58.3 |
Yes |
|
Lung |
30.3 |
31.0 |
No |
|
Melanoma of skin |
87.3 |
90.2 |
Yes |
|
Non-Hodgkin lymphoma |
26.4 |
25.1 |
No |
|
Oesophagus including cardia and gastroesophageal junction |
17.6 |
21.7 |
Yes |
|
Oral cavity, hard palate and lip (inner aspect) |
39.1 |
43.5 |
No |
|
Oropharynx, base of tongue, tonsil, soft palate and uvula |
46.0 |
62.4 |
Yes |
|
Ovary, fallopian tube and primary peritoneal carcinomas |
44.8 |
37.0 |
Yes |
|
Pancreas |
24.2 |
23.5 |
No |
|
Prostate |
50.9 |
55.0 |
Yes |
|
Rectum and rectosigmoid junction |
41.7 |
45.9 |
Yes |
|
Stomach excluding cardia and gastroesophageal junction* |
30.6 |
36.2 |
No |
|
Testis |
88.8 |
92.6 |
No |
|
Thyroid* |
87.8 |
88.2 |
No |
|
Uterus |
80.3 |
83.5 |
Yes |
* Staging completeness for 2019 was below 65% for cervix, stomach, and thyroid cancers.
Last edited: 9 November 2022 4:37 pm